Table 1 The relationship between characteristics and non-SLN metastasis
From: Prediction of nonsentinel lymph node metastasis in breast cancer patients based on machine learning
Characteristics | Overall | Without non-SLN metastasis | With non-SLN metastasis | p |
|---|---|---|---|---|
| Â | N = 1005 | n = 667 | n = 338 | Â |
Age (median [IQR]) | 51.00 (45.00, 59.00) | 51.00 (45.00, 60.00) | 51.00 (46.00, 59.00) | 0.951 |
Position (%) | Â | Â | Â | 0.592 |
 Left | 498 (49.6) | 326 (48.9) | 172 (50.9) |  |
 Right | 507 (50.4) | 341 (51.1) | 166 (49.1) | |
BMI (%) | Â | Â | Â | 0.004 |
 < 18.5 | 23 (2.3) | 13 (1.9) | 10 (3.0) |  |
 18.5–23.9 | 465 (46.3) | 332 (49.8) | 133 (39.3) | |
 24–27.9 | 385 (38.3) | 248 (37.2) | 137 (40.5) | |
 ≥ 28 | 132 (13.1) | 74 (11.1) | 58 (17.2) | |
Pregnant (%) | Â | Â | Â | 0.901 |
 0 | 48 (4.8) | 33 (4.9) | 15 (4.4) |  |
 1 | 652 (64.9) | 430 (64.5) | 222 (65.7) | |
 ≥ 2 | 305 (30.3) | 204 (30.6) | 101 (29.9) | |
Menopause (%) | Â | Â | Â | 0.828 |
 No | 488 (48.6) | 326 (48.9) | 162 (47.9) |  |
 Yes | 517 (51.4) | 341 (51.1) | 176 (52.1) | |
Nipple retraction (%) | Â | Â | Â | 0.104 |
 No | 954 (94.9) | 639 (95.8) | 315 (93.2) |  |
 Yes | 51 (5.1) | 28 (4.2) | 23 (6.8) |  |
Nipple discharge (%) | Â | Â | Â | 1 |
 No | 972 (96.7) | 645 (96.7) | 327 (96.7) |  |
 Yes | 33 (3.3) | 22 (3.3) | 11 (3.3) |  |
Number of tumor (%) | Â | Â | Â | 0.487 |
 Single focal | 900 (89.6) | 601 (90.1) | 299 (88.5) |  |
 Multi-focal | 105 (10.4) | 66 (9.9) | 39 (11.5) | |
cT (%) | Â | Â | Â | 0.042 |
 1 | 466 (46.4) | 328 (49.2) | 138 (40.8) |  |
 2 | 512 (50.9) | 321 (48.1) | 191 (56.5) | |
 3 | 19 (1.9) | 14 (2.1) | 5 (1.5) |  |
 4 | 8 (0.8) | 4 (0.6) | 4 (1.2) |  |
Aspect ratio (%) | Â | Â | Â | 0.867 |
 < 1 | 924 (91.9) | 615 (92.2) | 309 (91.4) |  |
 > 1 | 63 (6.3) | 41 (6.1) | 22 (6.5) |  |
 = 1 | 18 (1.8) | 11 (1.6) | 7 (2.1) |  |
US tumor borderline (%) | Â | Â | Â | 0.200 |
 Clear | 101 (10.0) | 75 (11.2) | 26 (7.7) |  |
 Lack of clarity | 246 (24.5) | 163 (24.4) | 83 (24.6) | |
 Blurring | 658 (65.5) | 429 (64.3) | 229 (67.8) | |
US tumor form (%) | Â | Â | Â | 0.080 |
 Rule | 57 (5.7) | 42 (6.3) | 15 (4.4) |  |
 Underrule | 54 (5.4) | 42 (6.3) | 12 (3.6) |  |
 Irregularity | 894 (89.0) | 583 (87.4) | 311 (92.0) | |
US tumor blood (%) | Â | Â | Â | 0.164 |
 No | 183 (18.2) | 130 (19.5) | 53 (15.7) |  |
 Yes | 822 (81.8) | 537 (80.5) | 285 (84.3) | |
cN (%) | Â | Â | Â | 0.001 |
 0 | 371 (36.9) | 272 (40.8) | 99 (29.3) |  |
 1 | 562 (55.9) | 348 (52.2) | 214 (63.3) | |
 2 | 3 (0.3) | 3 (0.4) | 0 (0.0) |  |
 3 | 69 (6.9) | 44 (6.6) | 25 (7.4) |  |
US BI-RADS (%) | Â | Â | Â | < 0.001 |
 3 | 24 (2.4) | 21 (3.1) | 3 (0.9) |  |
 4 | 811 (80.7) | 554 (83.1) | 257 (76.0) | |
 5 | 163 (16.2) | 87 (13.0) | 76 (22.5) | |
 6 | 7 (0.7) | 5 (0.7) | 2 (0.6) |  |
MG calcification (%) | Â | Â | Â | 0.653 |
 No | 257 (25.6) | 174 (26.1) | 83 (24.6) |  |
 Yes | 748 (74.4) | 493 (73.9) | 255 (75.4) | |
MG BI-RADS (%) | Â | Â | Â | 0.016 |
 3 | 97 (9.7) | 75 (11.2) | 22 (6.5) |  |
 4 | 741 (73.7) | 485 (72.7) | 256 (75.7) | |
 5 | 133 (13.2) | 80 (12.0) | 53 (15.7) | |
 6 | 34 (3.4) | 27 (4.0) | 7 (2.1) |  |
pT (%) | Â | Â | Â | 0.026 |
 1 | 629 (62.6) | 433 (64.9) | 196 (58.0) |  |
 2 | 361 (35.9) | 228 (34.2) | 133 (39.3) | |
 3 | 7 (0.7) | 2 (0.3) | 5 (1.5) |  |
 4 | 8 (0.8) | 4 (0.6) | 4 (1.2) |  |
pN (%) | Â | Â | Â | < 0.001 |
 0 | 82 (8.2) | 82 (12.3) | 0 (0.0) |  |
 1 | 734 (73.0) | 577 (86.5) | 157 (46.4) | |
 2 | 130 (12.9) | 8 (1.2) | 122 (36.1) | |
 3 | 59 (5.9) | 0 (0.0) | 59 (17.5) | |
SLNs group (%) | Â | Â | Â | 0.004 |
 Negative | 103 (10.2) | 82 (12.3) | 21 (6.2) |  |
 Positive | 902 (89.8) | 585 (87.7) | 317 (93.8) | |
SLNM (%) | Â | Â | Â | < 0.001 |
 0 | 103 (10.2) | 82 (12.3) | 21 (6.2) |  |
 1/2 | 789 (78.5) | 549 (82.3) | 240 (71.0) |  |
 ≥ 3 | 113 (11.2) | 36 (5.4) | 77 (22.8) |  |
Ratio of no. of positive SLNs to total no. of SLNs (%) | Â | Â | Â | < 0.001 |
 ≤ 0.5 | 738 (73.4) | 561 (84.1) | 177 (52.4) |  |
 > 0.5 | 267 (26.6) | 106 (15.9) | 161 (47.6) | |
Grade (%) | Â | Â | Â | 0.114 |
 1 | 18 (1.8) | 16 (2.4) | 2 (0.6) |  |
 2 | 768 (76.4) | 504 (75.6) | 264 (78.1) | |
 3 | 219 (21.8) | 147 (22.0) | 72 (21.3) | |
Pathological type (%) | Â | Â | Â | 0.345 |
 Invasive ductal carcinoma | 979 (97.4) | 647 (97.0) | 332 (98.2) |  |
 Others | 26 (2.6) | 20 (3.0) | 6 (1.8) |  |
Subtype (%) | Â | Â | Â | 0.650 |
 Luminal A | 99 (9.9) | 68 (10.2) | 31 (9.2) |  |
 Luminal B | 799 (79.5) | 523 (78.4) | 276 (81.7) | |
 TNBC | 47 (4.7) | 34 (5.1) | 13 (3.8) |  |
 HER-2 overexpression | 60 (6.0) | 42 (6.3) | 18 (5.3) |  |
ER (%) | Â | Â | Â | 0.118 |
 Negative | 153 (15.2) | 108 (16.2) | 45 (13.3) |  |
 Low | 19 (1.9) | 16 (2.4) | 3 (0.9) |  |
 High | 833 (82.9) | 543 (81.4) | 290 (85.8) | |
PR (%) | Â | Â | Â | 0.105 |
 Negative | 211 (21.0) | 150 (22.5) | 61 (18.0) |  |
 Low | 138 (13.7) | 83 (12.4) | 55 (16.3) | |
 High | 656 (65.3) | 434 (65.1) | 222 (65.7) | |
HER2 (%) | Â | Â | Â | 0.610 |
 Negative | 307 (30.5) | 197 (29.5) | 110 (32.5) |  |
 Low | 539 (53.6) | 362 (54.3) | 177 (52.4) | |
 Positive | 159 (15.8) | 108 (16.2) | 51 (15.1) | |
Ki-67 (%) | Â | Â | Â | 0.051 |
 ≤ 14 | 340 (33.8) | 240 (36.0) | 100 (29.6) |  |
 > 14 | 665 (66.2) | 427 (64.0) | 238 (70.4) | |
P53 (%) | Â | Â | Â | 0.106 |
 Negative | 351 (34.9) | 245 (36.7) | 106 (31.4) |  |
 Positive | 654 (65.1) | 422 (63.3) | 232 (68.6) | |
LVI (%) | Â | Â | Â | < 0.001 |
 No | 609 (60.6) | 444 (66.6) | 165 (48.8) |  |
 Yes | 396 (39.4) | 223 (33.4) | 173 (51.2) | |
Surgical method (%) | Â | Â | Â | 0.818 |
 BCS | 176 (17.5) | 115 (17.2) | 61 (18.0) |  |
 Mastectomy | 829 (82.5) | 552 (82.8) | 277 (82.0) | |